Very early cardiac hemodynamic changes after atrial fibrillation ablation Authors: Wanyu Hu, Shiquan Chen, Hui Cheng, Yankai Mao, Bowen Zhao, Shiyan Li, Bei Wang, Hailin Tang, Chenyang Jiang Published: 2025 ABSTRACT All chambers’ systolic functions were improved with long-term follow-up after catheter ablation (CA). However, changes on cardiac function on very early phase (within 48 h) has not been thoroughly investigated. This study aimed to evaluate the acute effects of CA on cardiac function and morphology immediately post-procedural (≤ 48 h). We prospectively enrolled 117 consecutive patients. Hemodynamic parameters including biatrial pressure and echocardiographic data were acquired pre- and post-ablation. (i) All bi-atrial pressures significantly elevated post-ablation (p < 0.002). (ii) Bi-atrial function including ejection fraction, reservoir strain and conduit strain improved immediately after ablation (p < 0.01). Persistent atrial fibrillation (AF) improved more than paroxysmal AF. (iii) Biventricular systolic function improved early but left ventricular diastolic function was stunned within 48 h (p < 0.01). Whereas all chambers’ volume did not change significantly (p > 0.05). (iv) No statistically significant differences in pre- versus post-procedural pressure changed between patients with persistent AF and those with paroxysmal AF in biatrial pressure elevation (p > 0.05). (v) Echocardiographic parameters including LA reservoir strain, RA reservoir strain, peak A of mitral valve, peak E of tricuspid valve and inferior vena cava diameters increased more in persistent AF groups (p < 0.05). This prospective study suggested all chambers’ systolic functions improved in early period post-ablation with left ventricular diastolic function stunning. Mechanical improvements preceding structural remodeling in AF patients early after ablation.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-28591-5. Introduction Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia and is associated with significantly increased mortality and morbidity1. AF causes cardiac dysfunction including biatrial systolic function2,3, biventricular systolic function and diastolic function4–6. Catheter ablation (CA) has emerged as a guideline-recommended treatment for symptomatic AF refractory to antiarrhythmic drug therapy7,8. CA facilitates reverse left atrial (LA) remodeling and improves LA function in AF patients in long-term follow-up9,10. Furthermore, CA significantly reduces overall mortality rates and decreases hospitalization for worsening heart failure by improving left ventricular (LV) ejection fraction (EF)11,12 and LV diastolic function4. Post-ablation period can be divided into acute, subacute and chronic phases. In the acute phase, edema and necrosis occur at the ablation site, while in the chronic phase, fibrosis with scar formation develops at the ablation site13,14. However, most studies on cardiac remodeling have focused on phase changes (more than 1 month) in the LA2,15–17 and LV15,18,19. Data on the acute phase (within 48 h) involving the atrial pressures and the function of LA, LV, right atrium (RA), and right ventricle (RV) remain limited. The impact of ablation on biventricular and biatrial function during the immediate postoperative period has not been thoroughly investigated. This prospective study aimed to evaluate the acute effects of CA on cardiac function and morphology across all chambers in patients with AF during the immediate post-procedural period (≤ 48 h). We consecutively enrolled 117 AF patients from a tertiary referral center. Hemodynamic assessments included direct measurements of left atrial pressure (LAP) and right atrial pressure (RAP). Comprehensive echocardiographic evaluation of all cardiac chambers’ dimensions and functions was performed at baseline and within 48 h post-ablation. Biatrial and biventricular functions were systematically analyzed using standardized protocols. Methods Study population We prospectively enrolled consecutive patients with persistent or paroxysmal AF undergoing CA at Sir Run Run Shaw Hospital (a tertiary referral center) between February 2024 and February 2025. Paroxysmal AF is characterized by termination within 7 days of onset, either spontaneously or with intervention. Persistent AF is characterized by continuous arrhythmia that lasts for more than 7 days20. Among 245 ablation procedures performed during this period, patients were included if they: (1) were ≥ 18 years old, (2) had documented AF, and (3) achieved immediate post-procedural sinus rhythm through radiofrequency ablation. Key exclusion criteria comprised: (1) valvular diseases (mitral valve (MV) prolapse, rheumatic heart disease); (2) congenital heart disease; (3) pericardial disorders (constrictive pericarditis); (4) cardiomyopathy (hypertrophic cardiomyopathy, restrictive cardiomyopathy, etc.); (5) moderate or severe valve regurgitation (significant MV regurgitation, aortic regurgitation and tricuspid regurgitation); (6) Systemic comorbidities (malignancy, connective tissue diseases). After screening based on the exclusion criteria, 117 patients (214 examinations) were ultimately enrolled in the study (Fig. 1). The Institutional Review Board of Sir Run Run Shaw Hospital approved the study protocol (Approval No. 2024-2517-01), which complied with Declaration of Helsinki principles. All participants provided written informed consent prior to enrollment.Fig. 1The flowchart of patient selection with atrial fibrillation. AF: atrial fibrillation; CA: catheter ablation; LAP: left atrial pressure; RAP: right atrial pressure. The flowchart of patient selection with atrial fibrillation. AF: atrial fibrillation; CA: catheter ablation; LAP: left atrial pressure; RAP: right atrial pressure. CA The ablation protocol typically involved pulmonary vein isolation to achieve electrical isolation. An intracardiac echocardiography catheter and sheaths were introduced via the femoral vein. Transseptal puncture was performed under intracardiac echocardiography guidance. The procedure utilized the Carto Sound three-dimensional mapping system (CARTO, Biosense Webster Inc.) with a 3.5 mm irrigated-tip catheter, equipped with contact-force sensing technology (Smart-Touch™, Biosense Webster Inc., Diamond Bar, CA, USA). Additional ablation, including linear ablation, substrate modification and superior vena cava isolation was performed at the operator’s discretion. The ablation settings were as follows: power 30-45W and irrigation flow rate 8–30 ml/min. Measurement of RAP and LAP The RAP and LAP were measured in all patients under stable fluid-loading conditions during CA. No new medications were administered during CA and echocardiography. RAP was measured after access via the femoral vein. LAP was measured immediately after transseptal puncture. Following successful restoration of sinus rhythm by CA, all patients underwent repeat atrial pressure measurement. Physicians used the same catheter system as that used pre-ablation to measure LAP/RAP post-ablation. They measured LAP/RAP parameters pre- and post-ablation included maximum LAP/RAP, mean LAP/RAP, and minimum LAP/RAP. LAP and RAP measurements were taken at end-expiration and represent the mean of ≥ 3 beats (Supplementary data online, Figure S1). The physician confirmed stable waveforms before recording. Echocardiography All participants underwent comprehensive transthoracic echocardiography using a Vivid E95 ultrasound system (GE Vingmed Ultrasound AS, Horten, Norway) equipped with an M5Sc transducer (1.4–4.6 MHz). Standardized examinations were performed: (1) within 1 week before CA, and (2) within 48 h post-procedure, following contemporary guidelines from the European Association of Cardiovascular Imaging and American Society of Echocardiography21,22. Thirty patients with persistent AF were in AF rhythm during pre-ablation echocardiographic assessment while nineteen patients were in sinus rhythm. Paroxysmal AF patients were in sinus rhythm during pre-ablation echocardiographic assessment. LV EF was obtained from parasternal long-axis views. Mitral and tricuspid inflow velocities were assessed by pulsed-wave Doppler (sample volume 1–2 mm at mitral or tricuspid leaflet tips) across 5 cardiac cycles in apical 4-chamber view. The diameter of the inferior vena cava (IVC) was measured perpendicular to its long axis, approximately 1–2 cm distal to the RA junction. Assessment of size and collapsibility percentage was performed during quiet respiration21. Apical two-chamber, three-chamber and four-chamber views were acquired for five consecutive cycles with frame rates exceeding 60 frames/s and stored for offline analysis later. LV global longitudinal strain (GLS) and LA strain were measured from LV-focused apical views (Supplementary data online, Figure S2). RV dimensions, RA strain and RV strain were measured from a RV-focused apical four-chamber view and two-chamber view according to the current recommendations (Supplementary data online, Figure S3)22,23. Echocardiographic data analysis Echocardiographic data were analysed offline by the same operator using proprietary software (version 204, EchoPAC, GE Vingmed Ultrasound, Norway). Measurements for all parameters from three (sinus rhythm) or five (AF) cardiac cycles were averaged. All Doppler measurements were performed at sweep speeds of 50–100 mm/s. LA, RA, LV and RV strains were analysed from measurement list in EchoPAC software according to current recommendations24. Timing of valvular events was measured from spectral Doppler recordings. The electrocardiogram R-wave trigger served as the zero strain reference. Endocardial border tracking was verified manually for all strain analyses. Statistical analysis All continuous data were presented as median (interquartile range) for non-normally distributed variables and mean ± standard deviation for normally distributed variables. All categorical data were expressed as numbers and percentages. The preprocedural and postprocedural hemodynamic parameters were analyzed using paired-sample t-tests. Comparisons between AF groups were performed using the independent t-test or Mann–Whitney U test as appropriate. Missing data were imputed using multiple imputation methods. All statistical analyses were performed using the SPSS package 27.0 (SPSS, Inc., Chicago, IL, USA). All statistical graphs were created using GraphPad Prism software (version 10; GraphPad Software, San Diego, CA). Composite figures were subsequently assembled using Adobe Illustrator (version 2023; Adobe Systems). Statistical significance was defined as p < 0.05. The study was exploratory across many parameters and p < 0.05 was applied uniformly without formal correction for multiple comparisons. Results Study population Among the 245 participants with AF undergoing CA, we excluded individuals with valvular diseases (n = 12), rheumatic heart disease (n = 10), cardiomyopathy (n = 8), moderate or severe valvular regurgitation (n = 56), congenital heart disease (n = 6), missing LAP and RAP data (n = 20), and missing pre- and post-ablation echocardiography data (n = 16). Finally, 117 patients (214 examinations) were included in the analysis (Fig. 1). Patients’ baseline characteristics and medications were shown in Table 1. Seventy-seven (65.8%) patients were male. Sixty-eight (58.1%) had paroxysmal AF and 49 (41.9%) had persistent AF. The mean age was 65.08 ± 10.14 years. Eleven (9.4%) patients had a history of stroke.Table 1Baseline characteristics before catheter ablation.VariablesValue (n = 117)Paroxysmal AF (n = 68)Persisitent AF (n = 49)p valueDemographic and co-morbidities Age (year)65.08 ± 10.1464.01 ± 10.8566.55 ± 8.960.183 Sex, male, n(%)77 (65.8%)44 (64.7%)33 (67.3%)0.766 Body surface area, (m2)1.77 ± 0.161.78 ± 0.151.76 ± 0.170.473 Body mass index, (kg/m2)24.43 ± 3.0624.61 ± 2.9924.17 ± 3.160.438 Heart rate, (beats/min)76.34 ± 18.7772.03 ± 17.7382.32 ± 18.710.003 Systolic blood pressure, (mmHg)125.36 ± 16.56125.32 ± 17.78125.42 ± 14.900.976 Diastolic blood pressure, (mmHg)77.45 ± 10.4576.10 ± 10.6379.31 ± 10.00.102 Cardiac function classification1 (1–2)1 (1–2)1 (1–2)0.978 CHA2DS2-VASc score2 (1–3)2 (1–3)2 (1–3)0.880 Diabetes, n (%)12 (10.3%)8 (11.8%)4 (8.2%)0.526 Hyperlipidemia, n (%)47 (40.2%)28 (41.2%)19 (38.8%)0.794 Coronary artery disease, n (%)8 (6.8%)5 (7.4%)3 (6.1%)0.999 Hypertension, n (%)61 (52.1%)38(55.9%)23 (46.9%)0.339 Chronic kidney disease, n (%)3 (2.6%)2(2.9%)1 (2%)0.999 Redo, n (%)24 (20.5%)15 (22.1%)9 (18.4%)0.626 Smoke, n (%)19 (16.2%)15 (22.1%)4 (8.2%)0.045 Drinking, n (%)18 (15.9%)12 (17.6%)6 (12.2%)0.424 Prior stroke/TIA, n (%)11 (9.4%)6 (8.8%)5 (10.2%)0.999AF type117 (100%)68 (58.1%)49 (41.9%)– Duration of AF atrial fibrillation (month)12 (2–29)12 (3–24)7 (1–36)0.801Laboratory findings Elevated creatinine, n (%)5 (4.3%)2 (2.9%)3 (6.1)0.707 Hemoglobin, (g/L)144.03 ± 15.89143.71 ± 15.38144.47 ± 16.730.799 Elevated pro-BNP or BNP, n (%)54 (46.2%)23 (33.8%)31 (63.3%)0.002Medications ACEI/ARB, n (%)42 (35.9%)28 (41.2%)14 (28.6%)0.161 MRA, n (%)5 (4.3%)1 (1.5%)4 (8.2%)0.193 Diuretics, n (%)9 (7.7%)3 (4.4%)6 (12.2%)0.224 SGLT2 inhibitor, n (%)5 (4.3%)3 (4.4%)2 (4.1%)0.999 Beta-blocker, n (%)51 (43.6%)32 (47.1%)19 (38.8%)0.373 Dihydropyridine Ca channel blocker, n (%)24 (20.5%)11 (16.2%)13 (26.5%)0.171 Digoxin, n (%)4 (3.4%)1 (1.5%)3 (6.1%)0.395 Anticoagulant, n (%)82 (70.1%)46 (67.6%)36 (73.5)0.497AF: atrial fibrillation; ACEI: Angiotensin-converting enzyme; ARB: angiotension II receptor blocker; MRA: mineralocorticoid receptor antagonist; SGLT2: sodium-glucose cotransporter-2 inhibitor.Data are expressed as mean ± SD, number (percentage), or median (interquartile range). Table 1Baseline characteristics before catheter ablation.VariablesValue (n = 117)Paroxysmal AF (n = 68)Persisitent AF (n = 49)p valueDemographic and co-morbidities Age (year)65.08 ± 10.1464.01 ± 10.8566.55 ± 8.960.183 Sex, male, n(%)77 (65.8%)44 (64.7%)33 (67.3%)0.766 Body surface area, (m2)1.77 ± 0.161.78 ± 0.151.76 ± 0.170.473 Body mass index, (kg/m2)24.43 ± 3.0624.61 ± 2.9924.17 ± 3.160.438 Heart rate, (beats/min)76.34 ± 18.7772.03 ± 17.7382.32 ± 18.710.003 Systolic blood pressure, (mmHg)125.36 ± 16.56125.32 ± 17.78125.42 ± 14.900.976 Diastolic blood pressure, (mmHg)77.45 ± 10.4576.10 ± 10.6379.31 ± 10.00.102 Cardiac function classification1 (1–2)1 (1–2)1 (1–2)0.978 CHA2DS2-VASc score2 (1–3)2 (1–3)2 (1–3)0.880 Diabetes, n (%)12 (10.3%)8 (11.8%)4 (8.2%)0.526 Hyperlipidemia, n (%)47 (40.2%)28 (41.2%)19 (38.8%)0.794 Coronary artery disease, n (%)8 (6.8%)5 (7.4%)3 (6.1%)0.999 Hypertension, n (%)61 (52.1%)38(55.9%)23 (46.9%)0.339 Chronic kidney disease, n (%)3 (2.6%)2(2.9%)1 (2%)0.999 Redo, n (%)24 (20.5%)15 (22.1%)9 (18.4%)0.626 Smoke, n (%)19 (16.2%)15 (22.1%)4 (8.2%)0.045 Drinking, n (%)18 (15.9%)12 (17.6%)6 (12.2%)0.424 Prior stroke/TIA, n (%)11 (9.4%)6 (8.8%)5 (10.2%)0.999AF type117 (100%)68 (58.1%)49 (41.9%)– Duration of AF atrial fibrillation (month)12 (2–29)12 (3–24)7 (1–36)0.801Laboratory findings Elevated creatinine, n (%)5 (4.3%)2 (2.9%)3 (6.1)0.707 Hemoglobin, (g/L)144.03 ± 15.89143.71 ± 15.38144.47 ± 16.730.799 Elevated pro-BNP or BNP, n (%)54 (46.2%)23 (33.8%)31 (63.3%)0.002Medications ACEI/ARB, n (%)42 (35.9%)28 (41.2%)14 (28.6%)0.161 MRA, n (%)5 (4.3%)1 (1.5%)4 (8.2%)0.193 Diuretics, n (%)9 (7.7%)3 (4.4%)6 (12.2%)0.224 SGLT2 inhibitor, n (%)5 (4.3%)3 (4.4%)2 (4.1%)0.999 Beta-blocker, n (%)51 (43.6%)32 (47.1%)19 (38.8%)0.373 Dihydropyridine Ca channel blocker, n (%)24 (20.5%)11 (16.2%)13 (26.5%)0.171 Digoxin, n (%)4 (3.4%)1 (1.5%)3 (6.1%)0.395 Anticoagulant, n (%)82 (70.1%)46 (67.6%)36 (73.5)0.497AF: atrial fibrillation; ACEI: Angiotensin-converting enzyme; ARB: angiotension II receptor blocker; MRA: mineralocorticoid receptor antagonist; SGLT2: sodium-glucose cotransporter-2 inhibitor.Data are expressed as mean ± SD, number (percentage), or median (interquartile range). Baseline characteristics before catheter ablation. AF: atrial fibrillation; ACEI: Angiotensin-converting enzyme; ARB: angiotension II receptor blocker; MRA: mineralocorticoid receptor antagonist; SGLT2: sodium-glucose cotransporter-2 inhibitor. Data are expressed as mean ± SD, number (percentage), or median (interquartile range). Both LAP and RAP elevated post ablation Among 117 patients, pre-ablation LAP measurements were obtained in 112 patients, while post-ablation LAP measurements were available for 105 patients. Similarly, pre-ablation RAP measurements were acquired in 97 patients and post-ablation RAP measurements in 96 patients. Pre- and post-procedure pressure comparisons were made only among patients with both measurements available. The mean LAP was 12.19 ± 5.35 mmHg pre-ablation and increased significantly to 15.98 ± 5.76 mmHg post-ablation. Similarly, mean RAP increased from 8.19 ± 4.17 mmHg pre-ablation to 10.79 ± 4.87 mmHg post-ablation. changes in LAP and RAP after ablation were shown in Table 2. All LAPs—including maximum, minimum, and mean pressures—demonstrated significant elevation post-ablation compared to pre-ablation values (p < 0.001 for all comparisons). This pattern was mirrored in RAP measurements, with maximum, minimum, and mean pressures significantly increased following the procedure (p < 0.001 for all comparisons) (Fig. 2). No patients experienced clinical symptoms or complications related to the acute pressure or diastolic changes such as acute heart failure, pulmonary edema, or hypotension in the 48 h post-CA.Table 2LAP and RAP changes after catheter ablation in AF patients.TotalPre-ablationPost-ablationp valuePOAF pre ablationPost ablationp valuePEAF pre ablationPost ablationp valueLAP min8.92 ± 6.127.36 ± 5.8310.49 ± 6.02< 0.0016.59 ± 5.5410.21 ± 5.20< 0.0018.42 ± 6.1010.86 ± 7.040.002LAP max21.21 ± 8.0718.77 ± 7.5123.64 ± 7.89< 0.00118.75 ± 7.8122.96 ± 8.11< 0.00118.81 ± 7.1624.60 ± 7.56< 0.001LAP mean14.08 ± 5.8612.19 ± 5.3515.98 ± 5.76< 0.00111.75 ± 5.2315.36 ± 5.46< 0.00112.79 ± 5.5016.84 ± 6.09< 0.001RAP min6.75 ± 4.895.42 ± 4.348.08 ± 5.06< 0.0014.99 ± 3.847.60 ± 4.82< 0.0016.02 ± 4.938.74 ± 5.36< 0.001RAP max12.78 ± 5.2311.53 ± 4.7714.03 ± 5.39< 0.00111.69 ± 4.7513.84 ± 5.570.00111.32 ± 4.8414.30 ± 5.16< 0.001RAP mean9.49 ± 4.718.19 ± 4.1710.79 ± 4.87< 0.0017.83 ± 3.7910.29 ± 4.69< 0.0018.71 ± 4.6511.49 ± 5.07< 0.001LAP: left atrial pressure; RAP: righr atrial pressure; AF:atrial fibrillation; POAF: paroxysmal atrial fibrillation; PEAF: persisitent atrial fibrillation.Data are expressed as mean ± SD.Fig. 2Left atrial pressure and right atrial pressure elevation post-ablation. LA: left atrial; RA: right atrial; max:maximum; min:minimum; pre: pre-ablation; post: post-ablation; ****p < 0.0001. Table 2LAP and RAP changes after catheter ablation in AF patients.TotalPre-ablationPost-ablationp valuePOAF pre ablationPost ablationp valuePEAF pre ablationPost ablationp valueLAP min8.92 ± 6.127.36 ± 5.8310.49 ± 6.02< 0.0016.59 ± 5.5410.21 ± 5.20< 0.0018.42 ± 6.1010.86 ± 7.040.002LAP max21.21 ± 8.0718.77 ± 7.5123.64 ± 7.89< 0.00118.75 ± 7.8122.96 ± 8.11< 0.00118.81 ± 7.1624.60 ± 7.56< 0.001LAP mean14.08 ± 5.8612.19 ± 5.3515.98 ± 5.76< 0.00111.75 ± 5.2315.36 ± 5.46< 0.00112.79 ± 5.5016.84 ± 6.09< 0.001RAP min6.75 ± 4.895.42 ± 4.348.08 ± 5.06< 0.0014.99 ± 3.847.60 ± 4.82< 0.0016.02 ± 4.938.74 ± 5.36< 0.001RAP max12.78 ± 5.2311.53 ± 4.7714.03 ± 5.39< 0.00111.69 ± 4.7513.84 ± 5.570.00111.32 ± 4.8414.30 ± 5.16< 0.001RAP mean9.49 ± 4.718.19 ± 4.1710.79 ± 4.87< 0.0017.83 ± 3.7910.29 ± 4.69< 0.0018.71 ± 4.6511.49 ± 5.07< 0.001LAP: left atrial pressure; RAP: righr atrial pressure; AF:atrial fibrillation; POAF: paroxysmal atrial fibrillation; PEAF: persisitent atrial fibrillation.Data are expressed as mean ± SD. LAP and RAP changes after catheter ablation in AF patients. LAP: left atrial pressure; RAP: righr atrial pressure; AF:atrial fibrillation; POAF: paroxysmal atrial fibrillation; PEAF: persisitent atrial fibrillation. Data are expressed as mean ± SD. Left atrial pressure and right atrial pressure elevation post-ablation. LA: left atrial; RA: right atrial; max:maximum; min:minimum; pre: pre-ablation; post: post-ablation; ****p < 0.0001. Association of AF type in LAP and RAP elevation We further investigated the impact of AF type on LAP and RAP before and after ablation. No statistically significant differences were observed in LAP elevation between persistent and paroxysmal AF patients. Post-ablation LAP measurements remained comparable between the two AF subtypes. Similarly, for RAP elevation, neither pre- nor post-procedural RAP levels differed significantly between persistent and paroxysmal AF groups (Table 3). The consistent lack of subtype-specific pressure differences suggested the acute post-ablation atrial hemodynamic changes may represent a universal response to procedural injury rather than being influenced by AF sbutype.Table 3Association of AF type in LAP and RAP elevations after ablation.Paroxysmal AFPersitent AFz or t valuep valueLAP min pre-ablation6.75 (4.00, 10.00)7.00 (3.50, 12.00)1.090.276LAP max pre-ablation17.95 (13.25, 21.75)18.00 (13.5, 23.00)0.4980.619LAP mean pre-ablation12.00 (9.00, 14.75)12.00 (9.00, 16.50)0.8660.386LAP min post-ablation11.00 (6.25, 14.00)9.14 (7.00, 12.24)− 0.3790.705LAP max post-ablation23.00 (17.05, 25.75)24.00 (17.50, 30.00)1.360.174LAP mean post-ablation15.36 ± 5.4616.84 ± 6.09− 1.380.170RAP min pre-ablation5.00 (2.25, 7.00)5.00 (2.56, 8.00)0.7120.477RAP max pre-ablation11.00 (9.00, 14.60)10.64 (7.50, 14.23)− 0.3900.696RAP mean pre-ablation8.00 (5.00, 10.01)8.09 (6.00, 10.000.8910.373RAP min post-ablation7.00 (4.00, 11.00)8.00 (5.07, 11.97)0.9320.351RAP max post-ablation13.72 (9.00, 18.00)14.12 (10.13, 16.98)0.4370.662RAP mean post-ablation9.75 (7.00, 13.73)11.00 (8.00, 15.00)1.0680.286ΔLAP min3.00 (1.00, 5.75)2.00 (− 1.00, 4.50)− 1.7850.074ΔLAP max4.00 (0.00, 8.00)6.00 (1.00, 9.50)1.2950.195ΔLAP mean3.00 (0.25, 7.00)3.00 (1.00, 7.00)0.2220.825ΔRAP min2.00 (0.00, 4.00)3.00 (0.00, 4.50)0.5330.594ΔRAP max2.00 (− 0.75, 5.00)2.00 (1.00, 6.00)1.0690.285ΔRAP mean2.00 (0.00, 4.75)3.00 (1.00, 5.00)0.7450.456AF: atrial fibrillation; LAP: left atial pressure; RAP: right atrial pressure; Δ: pressure post-ablation minus pre-ablation. Table 3Association of AF type in LAP and RAP elevations after ablation.Paroxysmal AFPersitent AFz or t valuep valueLAP min pre-ablation6.75 (4.00, 10.00)7.00 (3.50, 12.00)1.090.276LAP max pre-ablation17.95 (13.25, 21.75)18.00 (13.5, 23.00)0.4980.619LAP mean pre-ablation12.00 (9.00, 14.75)12.00 (9.00, 16.50)0.8660.386LAP min post-ablation11.00 (6.25, 14.00)9.14 (7.00, 12.24)− 0.3790.705LAP max post-ablation23.00 (17.05, 25.75)24.00 (17.50, 30.00)1.360.174LAP mean post-ablation15.36 ± 5.4616.84 ± 6.09− 1.380.170RAP min pre-ablation5.00 (2.25, 7.00)5.00 (2.56, 8.00)0.7120.477RAP max pre-ablation11.00 (9.00, 14.60)10.64 (7.50, 14.23)− 0.3900.696RAP mean pre-ablation8.00 (5.00, 10.01)8.09 (6.00, 10.000.8910.373RAP min post-ablation7.00 (4.00, 11.00)8.00 (5.07, 11.97)0.9320.351RAP max post-ablation13.72 (9.00, 18.00)14.12 (10.13, 16.98)0.4370.662RAP mean post-ablation9.75 (7.00, 13.73)11.00 (8.00, 15.00)1.0680.286ΔLAP min3.00 (1.00, 5.75)2.00 (− 1.00, 4.50)− 1.7850.074ΔLAP max4.00 (0.00, 8.00)6.00 (1.00, 9.50)1.2950.195ΔLAP mean3.00 (0.25, 7.00)3.00 (1.00, 7.00)0.2220.825ΔRAP min2.00 (0.00, 4.00)3.00 (0.00, 4.50)0.5330.594ΔRAP max2.00 (− 0.75, 5.00)2.00 (1.00, 6.00)1.0690.285ΔRAP mean2.00 (0.00, 4.75)3.00 (1.00, 5.00)0.7450.456AF: atrial fibrillation; LAP: left atial pressure; RAP: right atrial pressure; Δ: pressure post-ablation minus pre-ablation. Association of AF type in LAP and RAP elevations after ablation. AF: atrial fibrillation; LAP: left atial pressure; RAP: right atrial pressure; Δ: pressure post-ablation minus pre-ablation. All cardiac chambers’ systolic functions began to recover within 48 h after CA All cardiac chambers’ systolic functions began to recover in the very early postoperative period after AF ablation (Table 4). Data suggested significant improvement in LA reservoir strain (Sr), conduit strain (Scd) (p < 0.05), with particularly notable reduction in LA contractile strain (Sct). Atrial function improved more in the persistent AF group than in the paroxysmal AF group. Given that 61.2% of patients with persistent AF were in AF rhythm during baseline echocardiography, conversion from AF to sinus rhythm could account for part of the immediate functional improvement. However, no significant improvement was observed in LA morphological parameters (p > 0.05). Both LV GLS (from − 16.34 to − 17.72%, p < 0.001) and peak strain dispersion (from 60.84 to 53.3 ms, p = 0.007) showed marked improvement compared to preoperative values, indicating recovery of LV systolic function and synchrony post-procedure, though no statistically significant difference was found in LV EF, and LV structural parameters remained unchanged. RA function parameters RA Sr and RA Scd exhibited significant postoperative recovery, while RA Sct showed no significant alteration. RV functional parameters showed statistically significant improvement, including TV S’ peak velocity, TAPSE and RVFAC. (Fig. 3) While RV GLS and free wall strain exhibited a numerical trend toward improvement postoperatively (RV GLS: − 16.32% vs. − 17.03%; FWS: − 18.53% vs. − 18.82%), these changes did not reach statistical significance (p = 0.227 and p = 0.768, respectively). Similarly, neither RA nor RV structural parameters showed significant changes. Functional improvements were more pronounced in persistent AF patients than in paroxysmal AF patients across all chambers.Table 4Post-procedural echcardiography findings within 48 h after catheter ablation.Total (n = 117)Pre-ablationPost-ablationp valuePOAF pre-ablationpost-ablationp valuePEAF pre-ablationpost-ablationp valueBP and heart rate Systolic BP (mmHg)131.89 ± 19.59133.59 ± 20.05130.19 ± 19.040.065131.76 ± 20.91132.35 ± 20.030.800136.13 ± 18.71127.19 ± 17.330.002 Diastolic BP (mmHg)83.35 ± 13.0383.89 ± 13.7082.80 ± 12.360.39880.39 ± 11.4081.99 ± 12.280.26988.75 ± 15.1883.93 ± 12.510.035 Heart rate (beats/min)76.82 ± 14.8878.01 ± 16.9875.64 ± 12.390.11877.08 ± 20.1174.07 ± 12.590.14979.31 ± 11.3777.82 ± 11.880.500LA structural parameters LAAPD (mm)39.48 ± 5.3639.11 ± 5.6139.84 ± 5.100.08137.01 ± 5.1037.98 ± 4.470.06042.03 ± 4.9942.42 ± 4.820.573 LA max (ml)61.16 ± 21.5260.47 ± 21.4161.84 ± 21.700.33954.67 ± 19.7054.50 ± 19.690.92068.52 ± 21.2772.03 ± 20.360.168 LA min (ml)38.34 ± 19.6138.87 ± 20.1337.81 ± 19.150.42331.36 ± 16.8630.27 ± 16.880.47149.31 ± 19.7948.28 ± 17.210.669 LA PreA (ml)47.89 ± 20.1648.61 ± 20.8347.16 ± 19.530.34342.16 ± 17.9640.57 ± 17.870.36057.57 ± 21.3856.32 ± 18.140.651 LA volume (ml)62.49 ± 22.7162.63 ± 23.3762.35 ± 22.120.86456.22 ± 21.0855.71 ± 20.610.78171.53 ± 23.6971.56 ± 20.990.993 LA volume index(ml/m2)35.23 ± 12.8435.38 ± 13.4535.09 ± 12.260.76431.12 ± 12.1731.21 ± 11.290.92841.29 ± 13.0040.48 ± 11.590.657 LA stiffness0.83 (0.55, 1.36)0.78 (0.46, 1.22)0.95 (0.60, 1.45)0.3450.57 (0.35, 0.88)0.72 (0.48, 1.13)0.2821.00 (0.79, 1.63)1.33 (0.84, 1.97)0.732LA function LA EF (%)40.13 ± 15.1038.71 ± 15.9441.55 ± 14.130.01245.53 ± 15.7847.17 ± 13.920.29529.23 ± 10.4433.74 ± 10.260.006 LA reservior strain (%)17.22 ± 8.6016.49 ± 9.0117.95 ± 8.140.01820.35 ± 9.2421.10 ± 8.700.41811.13 ± 5.1613.57 ± 4.550.001 LA conduit strain (%)− 10.33 ± 5.34− 9.22 ± 5.70− 11.43 ± 4.73< 0.0001− 10.23 ± 6.44− 12.59 ± 5.340.005− 7.82 ± 4.13− 9.82 ± 3.110.007 LA contractile strain (%)− 6.66 ± 5.48− 8.52 ± 7.56− 6.45 ± 5.130.001− 9.39 ± 5.70− 8.38 ± 5.210.092− 3.40 ± 3.94− 3.77 ± 3.600.526RA structural parameters RA max (ml)41.44 ± 17.6440.87 ± 16.6242.00 ± 18.660.48238.16 ± 14.7038.72 ± 20.510.78344.63 ± 18.4746.56 ± 14.770.470 RA min (ml)23.68 ± 14.6225.29 ± 14.8622.06 ± 14.250.00421.21 ± 12.8017.99 ± 14.330.01330.97 ± 15.7527.70 ± 12.180.109 RA preA (ml)32.10 ± 14.7233.16 ± 14.4031.04 ± 15.010.13429.85 ± 11.4527.44 ± 15.300.15437.74 ± 16.7736.04 ± 13.200.487 RA area (cm2)17.02 ± 4.6116.68 ± 4.3217.35 ± 4.870.09815.69 ± 4.0616.14 ± 4.770.34818.05 ± 4.3519.03 ± 4.530.168 RA volume index (ml/m2)23.25 ± 10.1122.80 ± 9.8123.70 ± 10.420.32320.74 ± 8.1521.67 ± 11.280.41325.65 ± 11.2226.53 ± 8.420.571RA function RA reservior strain (%)25.15 ± 12.0822.33 ± 12.1527.96 ± 11.38< 0.000127.66 ± 12.4730.97 ± 12.020.06014.95 ± 6.6223.79 ± 8.98< 0.0001 RA conduit strain (%)− 16.16 ± 8.25− 13.66 ± 7.84− 18.66 ± 7.92< 0.0001− 15.62 ± 8.68− 19.85 ± 8.750.001− 10.94 ± 5.51− 17.00 ± 6.31< 0.0001 RA contractile strain (%)− 8.89 ± 7.18− 8.52 ± 7.56− 9.26 ± 6.790.32411.88 ± 7.10− 11.18 ± 6.920.500− 3.85 ± 5.42− 6.60 ± 5.670.008 RA EF (%)45.19 ± 16.0041.24 ± 15.8149.13 ± 15.26< 0.000147.21 ± 14.6554.59 ± 13.44< 0.000132.96 ± 13.5741.56 ± 14.500.001LV structural parameters IVSd (mm)9.63 ± 1.479.55 ± 1.499.70 ± 1.450.3179.59 ± 1.479.93 ± 1.440.0809.51 ± 1.539.39 ± 1.430.633 LVIDd (mm)48.17 ± 4.2847.94 ± 4.4448.41 ± 4.120.28447.28 ± 4.6947.38 ± 4.040.87748.84 ± 3.9449.84 ± 3.840.119 LVPWd (mm)9.34 ± 1.259.36 ± 1.289.32 ± 1.230.7809.23 ± 1.229.35 ± 1.210.5059.54 ± 1.359.28 ± 1.270.266 End-diastolic volume (ml)110.01 ± 21.54108.32 ± 21.70111.71 ± 21.350.119104.65 ± 22.29105.72 ± 20.390.709113.41 ± 19.96120.02 ± 19.990.049 End-systolic volume (ml)36.24 ± 10.9835.39 ± 10.8037.09 ± 11.130.09632.91 ± 10.0733.95 ± 8.950.41138.83 ± 10.9441.45 ± 12.410.126 Relative wall thickness0.38 ± 0.060.38 ± 0.070.38 ± 0.050.8960.39 ± 0.080.39 ± 0.050.2920.37 ± 0.070.37 ± 0.050.610LV systolic function LV EF (%)67.53 ± 6.0467.74 ± 6.2267.33 ± 5.860.53069.12 ± 5.4467.94 ± 4.910.16165.83 ± 6.7866.48 ± 6.940.542 Fractional shortening (%)37.73 ± 4.5737.85 ± 4.7437.62 ± 4.410.66738.83 ± 4.3238.03 ± 3.990.24536.49 ± 4.9937.05 ± 4.930.515 LV GLS (%)− 17.03 ± 3.61− 16.34 ± 3.86− 17.72 ± 3.20< 0.0001− 17.73 ± 3.12− 18.62 ± 3.100.032− 14.41 ± 3.99− 16.46 ± 2.94< 0.0001 Peak systolic delay (ms)57.07 ± 27.0160.84 ± 27.9153.30 ± 25.650.00758.32 ± 24.8053.44 ± 29.240.15464.34 ± 31.6653.11 ± 19.920.018LV diastolic function MV E (cm/s)85.33 ± 19.2981.49 ± 19.5189.18 ± 18.36< 0.000175.70 ± 14.8486.50 ± 18.75< 0.000189.53 ± 22.3492.89 ± 17.320.232 E wave acceleration (m/s2)16.04 ± 13.4516.69 ± 16.8915.39 ± 8.790.43612.57 ± 5.3714.79 ± 8.540.04622.40 ± 24.3316.21 ± 9.160.091 E wave deceleration time (ms)167.77 ± 60.75169.69 ± 64.62165.85 ± 56.830.522185.86 ± 71.88169.88 ± 61.820.064147.24 ± 44.66160.28 ± 49.150.085 MV A (cm/s)––––63.64 ± 20.5759.73 ± 19.980.080––– MV E/A––––1.34 ± 0.531.68 ± 0.860.003––– MED E’ (cm/s)8.20 ± 1.728.34 ± 1.958.06 ± 1.450.1208.14 ± 1.888.12 ± 1.390.9208.60 ± 2.047.97 ± 1.550.038 LAT E’ (cm/s)10.43 ± 2.5411.44 ± 2.409.43 ± 2.27< 0.000111.27 ± 2.389.52 ± 2.22< 0.000111.67 ± 2.439.30 ± 2.36< 0.0001 MED E/E'10.79 ± 3.0510.17 ± 3.0211.41 ± 2.96< 0.00019.72 ± 2.8610.93 ± 2.880.00110.80 ± 3.1512.07 ± 2.970.004 LAT E/E'8.63 ± 2.767.43 ± 2.309.83 ± 2.67< 0.00017.05 ± 2.019.44 ± 2.77< 0.00017.96 ± 2.5710.35 ± 2.45< 0.0001 Mean E/E'9.51 ± 2.688.58 ± 2.5210.44 ± 2.52< 0.00018.16 ± 2.2410.03 ± 2.58< 0.00019.16 ± 2.7811.00 ± 2.34< 0.0001 MV Vp (cm/s)70.81 ± 27.9768.67 ± 29.2772.94 ± 26.560.14966.56 ± 23.2771.82 ± 23.920.16571.60 ± 36.0474.51 ± 30.030.546 E/Vp1.44 ± 0.711.39 ± 0.751.48 ± 0.660.2091.35 ± 0.761.42 ± 0.630.5221.45 ± 0.751.56 ± 0.710.201 PV S wave (cm/s)58.45 ± 16.2553.22 ± 13.3463.67 ± 17.25< 0.000154.99 ± 14.5363.01 ± 17.560.00350.78 ± 11.1864.59 ± 16.93< 0.0001 PV D wave (cm/s)48.82 ± 16.4845.78 ± 15.7651.85 ± 16.700.00246.45 ± 14.5654.29 ± 17.560.00144.86 ± 17.3948.47 ± 14.950.265 PV atrial reversal wave (cm/s)30.97 ± 7.6830.43 ± 7.3431.52 ± 8.000.23630.61 ± 8.0732.45 ± 8.330.17430.17 ± 6.2730.23 ± 7.400.961 PV atrial reversal duration (ms)164.70 ± 43.27163.52 ± 39.25165.88 ± 47.080.658156.63 ± 33.54163.82 ± 47.930.292173.09 ± 44.64168.74 ± 46.220.614 PV S/D1.32 ± 0.511.29 ± 0.501.35 ± 0.520.3321.27 ± 0.501.25 ± 0.480.7221.32 ± 0.491.49 ± 0.540.076 PV D duration (ms)132.90 ± 50.93137.31 ± 50.57128.50 ± 51.120.190134.17 ± 46.92133.29 ± 54.440.919141.66 ± 55.45121.85 ± 45.840.065 IVRT (ms)73.31 ± 18.4675.64 ± 17.9871.00 ± 18.720.00377.00 ± 18.3071.91 ± 19.880.02173.74 ± 17.5369.71 ± 17.100.055 Peak TR velocity (m/s)2.67 ± 0.362.59 ± 0.372.74 ± 0.33< 0.00012.58 ± 0.372.67 ± 0.320.0862.60 ± 0.372.84 ± 0.34< 0.0001 RV Systolic Pressure (mmHg)34.30 ± 7.8132.22 ± 6.9836.39 ± 8.05< 0.000131.34 ± 6.7834.75 ± 7.180.00133.44 ± 7.1438.67 ± 8.70< 0.0001RV systolic function TV S’ peak (cm/s)13.20 ± 2.6011.92 ± 2.0314.48 ± 2.48< 0.000112.17 ± 1.9515.10 ± 2.54< 0.000111.57 ± 2.1113.62 ± 2.14< 0.0001 TAPSE (mm)20.27 ± 3.1019.58 ± 3.0520.96 ± 3.00< 0.000120.32 ± 3.1721.17 ± 3.140.10018.54 ± 2.5820.67 ± 2.79< 0.0001 RV fractional area change (%)47.36 ± 7.6146.04 ± 7.1948.68 ± 7.820.00547.41 ± 7.4548.88 ± 7.250.18944.12 ± 6.4048.40 ± 8.610.008 RV GLS (%)− 16.67 ± 5.20− 16.32 ± 5.06− 17.03 ± 5.340.227'− 17.81 ± 4.76− 17.69 ± 5.490.872'− 14.25 ± 4.78'− 16.11 ± 5.030.059 Free wall strain (%)− 18.67 ± 7.94− 18.53 ± 6.59− 18.82 ± 9.120.768− 20.24 ± 5.92− 19.08 ± 9.960.391− 16.15 ± 6.79− 18.46 ± 7.900.117RV diastolic function TV E peak (cm/s)57.06 ± 17.5654.31 ± 15.9259.81 ± 18.710.00652.50 ± 14.3861.78 ± 20.23< 0.000156.83 ± 17.6957.08 ± 16.190.933 TV A peak (cm/s)––––42.65 ± 13.4849.88 ± 19.250.007––– TV E/A––––1.36 ± 0.481.30 ± 0.340.358––– TV E’ (cm/s)12.42 ± 3.2412.03 ± 3.2712.82 ± 3.180.04510.99 ± 2.7912.35 ± 2.940.00513.48 ± 3.3513.46 ± 3.410.977 TV E/E'4.86 ± 1.944.81 ± 2.034.91 ± 1.840.5815.09 ± 2.335.25 ± 1.940.5584.42 ± 1.484.44 ± 1.590.921 IVC max (mm)13.19 ± 4.0912.21 ± 3.7914.16 ± 4.16< 0.000112.14 ± 3.8913.13 ± 4.100.06912.31 ± 3.7015.59 ± 3.85< 0.0001 IVC min (mm)5.79 ± 3.144.85 ± 2.216.74 ± 3.63< 0.00014.93 ± 2.496.10 ± 3.590.0064.73 ± 1.767.63 ± 3.54< 0.0001 IVC-collapsibility index (%)57.45 ± 10.8460.47 ± 7.0754.43 ± 12.95< 0.000160.31 ± 7.3856.00 ± 11.420.00560.69 ± 6.6852.24 ± 14.660.001POAF: paroxysmal atrial fibrillation; PEAF: persisitent atrial fibrillation; BP: blood pressure; LA: left atrial; LAAPD: left atrial anteroposterior diamete; EF: ejection fraction; RA: right atrial; LV: left ventricular; GLS: global longitudinal strain; MV: mitral valve; E:early filling; A: late filling; E': early diastolic; VP: velocity of propagation; PV: pulmonary vein; IVRT: isovolumic relaxation time; TR: tricuspid regurgitation; RV: right ventricular; TV: tricuspid valve; TAPSE: tricuspid annular plane systolic excursion; IVC: inferior vena cava.Data are expressed as mean ± SD.Fig. 3Functional changes of all cardiac chambers after ablation within 48 h. LA: left atrial; RA: right atrial; LAEF: left atrial ejection fraction; LASr: left atrial reservoir strain; LAScd: left atrial conduit strain; LASct: left atrial contractile strain; RAEF: right atrial ejection fraction; RASr: right atrial reservoir strain; RAScd: right atrial conduit strain; RASct: right atrial contractile strain; LV GLS: left ventricular global longitudinal strain; PSD: peak strain dispersion; LV EF: left ventricular ejection fraction; TV S’: tricuspid annular peak systolic velocity; TAPSE: tricuspid annular plane systolic excursion; RVFAC: right ventricular fractional area change; pre: pre-ablation; post: post-ablation; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns: not significant. Table 4Post-procedural echcardiography findings within 48 h after catheter ablation.Total (n = 117)Pre-ablationPost-ablationp valuePOAF pre-ablationpost-ablationp valuePEAF pre-ablationpost-ablationp valueBP and heart rate Systolic BP (mmHg)131.89 ± 19.59133.59 ± 20.05130.19 ± 19.040.065131.76 ± 20.91132.35 ± 20.030.800136.13 ± 18.71127.19 ± 17.330.002 Diastolic BP (mmHg)83.35 ± 13.0383.89 ± 13.7082.80 ± 12.360.39880.39 ± 11.4081.99 ± 12.280.26988.75 ± 15.1883.93 ± 12.510.035 Heart rate (beats/min)76.82 ± 14.8878.01 ± 16.9875.64 ± 12.390.11877.08 ± 20.1174.07 ± 12.590.14979.31 ± 11.3777.82 ± 11.880.500LA structural parameters LAAPD (mm)39.48 ± 5.3639.11 ± 5.6139.84 ± 5.100.08137.01 ± 5.1037.98 ± 4.470.06042.03 ± 4.9942.42 ± 4.820.573 LA max (ml)61.16 ± 21.5260.47 ± 21.4161.84 ± 21.700.33954.67 ± 19.7054.50 ± 19.690.92068.52 ± 21.2772.03 ± 20.360.168 LA min (ml)38.34 ± 19.6138.87 ± 20.1337.81 ± 19.150.42331.36 ± 16.8630.27 ± 16.880.47149.31 ± 19.7948.28 ± 17.210.669 LA PreA (ml)47.89 ± 20.1648.61 ± 20.8347.16 ± 19.530.34342.16 ± 17.9640.57 ± 17.870.36057.57 ± 21.3856.32 ± 18.140.651 LA volume (ml)62.49 ± 22.7162.63 ± 23.3762.35 ± 22.120.86456.22 ± 21.0855.71 ± 20.610.78171.53 ± 23.6971.56 ± 20.990.993 LA volume index(ml/m2)35.23 ± 12.8435.38 ± 13.4535.09 ± 12.260.76431.12 ± 12.1731.21 ± 11.290.92841.29 ± 13.0040.48 ± 11.590.657 LA stiffness0.83 (0.55, 1.36)0.78 (0.46, 1.22)0.95 (0.60, 1.45)0.3450.57 (0.35, 0.88)0.72 (0.48, 1.13)0.2821.00 (0.79, 1.63)1.33 (0.84, 1.97)0.732LA function LA EF (%)40.13 ± 15.1038.71 ± 15.9441.55 ± 14.130.01245.53 ± 15.7847.17 ± 13.920.29529.23 ± 10.4433.74 ± 10.260.006 LA reservior strain (%)17.22 ± 8.6016.49 ± 9.0117.95 ± 8.140.01820.35 ± 9.2421.10 ± 8.700.41811.13 ± 5.1613.57 ± 4.550.001 LA conduit strain (%)− 10.33 ± 5.34− 9.22 ± 5.70− 11.43 ± 4.73< 0.0001− 10.23 ± 6.44− 12.59 ± 5.340.005− 7.82 ± 4.13− 9.82 ± 3.110.007 LA contractile strain (%)− 6.66 ± 5.48− 8.52 ± 7.56− 6.45 ± 5.130.001− 9.39 ± 5.70− 8.38 ± 5.210.092− 3.40 ± 3.94− 3.77 ± 3.600.526RA structural parameters RA max (ml)41.44 ± 17.6440.87 ± 16.6242.00 ± 18.660.48238.16 ± 14.7038.72 ± 20.510.78344.63 ± 18.4746.56 ± 14.770.470 RA min (ml)23.68 ± 14.6225.29 ± 14.8622.06 ± 14.250.00421.21 ± 12.8017.99 ± 14.330.01330.97 ± 15.7527.70 ± 12.180.109 RA preA (ml)32.10 ± 14.7233.16 ± 14.4031.04 ± 15.010.13429.85 ± 11.4527.44 ± 15.300.15437.74 ± 16.7736.04 ± 13.200.487 RA area (cm2)17.02 ± 4.6116.68 ± 4.3217.35 ± 4.870.09815.69 ± 4.0616.14 ± 4.770.34818.05 ± 4.3519.03 ± 4.530.168 RA volume index (ml/m2)23.25 ± 10.1122.80 ± 9.8123.70 ± 10.420.32320.74 ± 8.1521.67 ± 11.280.41325.65 ± 11.2226.53 ± 8.420.571RA function RA reservior strain (%)25.15 ± 12.0822.33 ± 12.1527.96 ± 11.38< 0.000127.66 ± 12.4730.97 ± 12.020.06014.95 ± 6.6223.79 ± 8.98< 0.0001 RA conduit strain (%)− 16.16 ± 8.25− 13.66 ± 7.84− 18.66 ± 7.92< 0.0001− 15.62 ± 8.68− 19.85 ± 8.750.001− 10.94 ± 5.51− 17.00 ± 6.31< 0.0001 RA contractile strain (%)− 8.89 ± 7.18− 8.52 ± 7.56− 9.26 ± 6.790.32411.88 ± 7.10− 11.18 ± 6.920.500− 3.85 ± 5.42− 6.60 ± 5.670.008 RA EF (%)45.19 ± 16.0041.24 ± 15.8149.13 ± 15.26< 0.000147.21 ± 14.6554.59 ± 13.44< 0.000132.96 ± 13.5741.56 ± 14.500.001LV structural parameters IVSd (mm)9.63 ± 1.479.55 ± 1.499.70 ± 1.450.3179.59 ± 1.479.93 ± 1.440.0809.51 ± 1.539.39 ± 1.430.633 LVIDd (mm)48.17 ± 4.2847.94 ± 4.4448.41 ± 4.120.28447.28 ± 4.6947.38 ± 4.040.87748.84 ± 3.9449.84 ± 3.840.119 LVPWd (mm)9.34 ± 1.259.36 ± 1.289.32 ± 1.230.7809.23 ± 1.229.35 ± 1.210.5059.54 ± 1.359.28 ± 1.270.266 End-diastolic volume (ml)110.01 ± 21.54108.32 ± 21.70111.71 ± 21.350.119104.65 ± 22.29105.72 ± 20.390.709113.41 ± 19.96120.02 ± 19.990.049 End-systolic volume (ml)36.24 ± 10.9835.39 ± 10.8037.09 ± 11.130.09632.91 ± 10.0733.95 ± 8.950.41138.83 ± 10.9441.45 ± 12.410.126 Relative wall thickness0.38 ± 0.060.38 ± 0.070.38 ± 0.050.8960.39 ± 0.080.39 ± 0.050.2920.37 ± 0.070.37 ± 0.050.610LV systolic function LV EF (%)67.53 ± 6.0467.74 ± 6.2267.33 ± 5.860.53069.12 ± 5.4467.94 ± 4.910.16165.83 ± 6.7866.48 ± 6.940.542 Fractional shortening (%)37.73 ± 4.5737.85 ± 4.7437.62 ± 4.410.66738.83 ± 4.3238.03 ± 3.990.24536.49 ± 4.9937.05 ± 4.930.515 LV GLS (%)− 17.03 ± 3.61− 16.34 ± 3.86− 17.72 ± 3.20< 0.0001− 17.73 ± 3.12− 18.62 ± 3.100.032− 14.41 ± 3.99− 16.46 ± 2.94< 0.0001 Peak systolic delay (ms)57.07 ± 27.0160.84 ± 27.9153.30 ± 25.650.00758.32 ± 24.8053.44 ± 29.240.15464.34 ± 31.6653.11 ± 19.920.018LV diastolic function MV E (cm/s)85.33 ± 19.2981.49 ± 19.5189.18 ± 18.36< 0.000175.70 ± 14.8486.50 ± 18.75< 0.000189.53 ± 22.3492.89 ± 17.320.232 E wave acceleration (m/s2)16.04 ± 13.4516.69 ± 16.8915.39 ± 8.790.43612.57 ± 5.3714.79 ± 8.540.04622.40 ± 24.3316.21 ± 9.160.091 E wave deceleration time (ms)167.77 ± 60.75169.69 ± 64.62165.85 ± 56.830.522185.86 ± 71.88169.88 ± 61.820.064147.24 ± 44.66160.28 ± 49.150.085 MV A (cm/s)––––63.64 ± 20.5759.73 ± 19.980.080––– MV E/A––––1.34 ± 0.531.68 ± 0.860.003––– MED E’ (cm/s)8.20 ± 1.728.34 ± 1.958.06 ± 1.450.1208.14 ± 1.888.12 ± 1.390.9208.60 ± 2.047.97 ± 1.550.038 LAT E’ (cm/s)10.43 ± 2.5411.44 ± 2.409.43 ± 2.27< 0.000111.27 ± 2.389.52 ± 2.22< 0.000111.67 ± 2.439.30 ± 2.36< 0.0001 MED E/E'10.79 ± 3.0510.17 ± 3.0211.41 ± 2.96< 0.00019.72 ± 2.8610.93 ± 2.880.00110.80 ± 3.1512.07 ± 2.970.004 LAT E/E'8.63 ± 2.767.43 ± 2.309.83 ± 2.67< 0.00017.05 ± 2.019.44 ± 2.77< 0.00017.96 ± 2.5710.35 ± 2.45< 0.0001 Mean E/E'9.51 ± 2.688.58 ± 2.5210.44 ± 2.52< 0.00018.16 ± 2.2410.03 ± 2.58< 0.00019.16 ± 2.7811.00 ± 2.34< 0.0001 MV Vp (cm/s)70.81 ± 27.9768.67 ± 29.2772.94 ± 26.560.14966.56 ± 23.2771.82 ± 23.920.16571.60 ± 36.0474.51 ± 30.030.546 E/Vp1.44 ± 0.711.39 ± 0.751.48 ± 0.660.2091.35 ± 0.761.42 ± 0.630.5221.45 ± 0.751.56 ± 0.710.201 PV S wave (cm/s)58.45 ± 16.2553.22 ± 13.3463.67 ± 17.25< 0.000154.99 ± 14.5363.01 ± 17.560.00350.78 ± 11.1864.59 ± 16.93< 0.0001 PV D wave (cm/s)48.82 ± 16.4845.78 ± 15.7651.85 ± 16.700.00246.45 ± 14.5654.29 ± 17.560.00144.86 ± 17.3948.47 ± 14.950.265 PV atrial reversal wave (cm/s)30.97 ± 7.6830.43 ± 7.3431.52 ± 8.000.23630.61 ± 8.0732.45 ± 8.330.17430.17 ± 6.2730.23 ± 7.400.961 PV atrial reversal duration (ms)164.70 ± 43.27163.52 ± 39.25165.88 ± 47.080.658156.63 ± 33.54163.82 ± 47.930.292173.09 ± 44.64168.74 ± 46.220.614 PV S/D1.32 ± 0.511.29 ± 0.501.35 ± 0.520.3321.27 ± 0.501.25 ± 0.480.7221.32 ± 0.491.49 ± 0.540.076 PV D duration (ms)132.90 ± 50.93137.31 ± 50.57128.50 ± 51.120.190134.17 ± 46.92133.29 ± 54.440.919141.66 ± 55.45121.85 ± 45.840.065 IVRT (ms)73.31 ± 18.4675.64 ± 17.9871.00 ± 18.720.00377.00 ± 18.3071.91 ± 19.880.02173.74 ± 17.5369.71 ± 17.100.055 Peak TR velocity (m/s)2.67 ± 0.362.59 ± 0.372.74 ± 0.33< 0.00012.58 ± 0.372.67 ± 0.320.0862.60 ± 0.372.84 ± 0.34< 0.0001 RV Systolic Pressure (mmHg)34.30 ± 7.8132.22 ± 6.9836.39 ± 8.05< 0.000131.34 ± 6.7834.75 ± 7.180.00133.44 ± 7.1438.67 ± 8.70< 0.0001RV systolic function TV S’ peak (cm/s)13.20 ± 2.6011.92 ± 2.0314.48 ± 2.48< 0.000112.17 ± 1.9515.10 ± 2.54< 0.000111.57 ± 2.1113.62 ± 2.14< 0.0001 TAPSE (mm)20.27 ± 3.1019.58 ± 3.0520.96 ± 3.00< 0.000120.32 ± 3.1721.17 ± 3.140.10018.54 ± 2.5820.67 ± 2.79< 0.0001 RV fractional area change (%)47.36 ± 7.6146.04 ± 7.1948.68 ± 7.820.00547.41 ± 7.4548.88 ± 7.250.18944.12 ± 6.4048.40 ± 8.610.008 RV GLS (%)− 16.67 ± 5.20− 16.32 ± 5.06− 17.03 ± 5.340.227'− 17.81 ± 4.76− 17.69 ± 5.490.872'− 14.25 ± 4.78'− 16.11 ± 5.030.059 Free wall strain (%)− 18.67 ± 7.94− 18.53 ± 6.59− 18.82 ± 9.120.768− 20.24 ± 5.92− 19.08 ± 9.960.391− 16.15 ± 6.79− 18.46 ± 7.900.117RV diastolic function TV E peak (cm/s)57.06 ± 17.5654.31 ± 15.9259.81 ± 18.710.00652.50 ± 14.3861.78 ± 20.23< 0.000156.83 ± 17.6957.08 ± 16.190.933 TV A peak (cm/s)––––42.65 ± 13.4849.88 ± 19.250.007––– TV E/A––––1.36 ± 0.481.30 ± 0.340.358––– TV E’ (cm/s)12.42 ± 3.2412.03 ± 3.2712.82 ± 3.180.04510.99 ± 2.7912.35 ± 2.940.00513.48 ± 3.3513.46 ± 3.410.977 TV E/E'4.86 ± 1.944.81 ± 2.034.91 ± 1.840.5815.09 ± 2.335.25 ± 1.940.5584.42 ± 1.484.44 ± 1.590.921 IVC max (mm)13.19 ± 4.0912.21 ± 3.7914.16 ± 4.16< 0.000112.14 ± 3.8913.13 ± 4.100.06912.31 ± 3.7015.59 ± 3.85< 0.0001 IVC min (mm)5.79 ± 3.144.85 ± 2.216.74 ± 3.63< 0.00014.93 ± 2.496.10 ± 3.590.0064.73 ± 1.767.63 ± 3.54< 0.0001 IVC-collapsibility index (%)57.45 ± 10.8460.47 ± 7.0754.43 ± 12.95< 0.000160.31 ± 7.3856.00 ± 11.420.00560.69 ± 6.6852.24 ± 14.660.001POAF: paroxysmal atrial fibrillation; PEAF: persisitent atrial fibrillation; BP: blood pressure; LA: left atrial; LAAPD: left atrial anteroposterior diamete; EF: ejection fraction; RA: right atrial; LV: left ventricular; GLS: global longitudinal strain; MV: mitral valve; E:early filling; A: late filling; E': early diastolic; VP: velocity of propagation; PV: pulmonary vein; IVRT: isovolumic relaxation time; TR: tricuspid regurgitation; RV: right ventricular; TV: tricuspid valve; TAPSE: tricuspid annular plane systolic excursion; IVC: inferior vena cava.Data are expressed as mean ± SD. Post-procedural echcardiography findings within 48 h after catheter ablation. POAF: paroxysmal atrial fibrillation; PEAF: persisitent atrial fibrillation; BP: blood pressure; LA: left atrial; LAAPD: left atrial anteroposterior diamete; EF: ejection fraction; RA: right atrial; LV: left ventricular; GLS: global longitudinal strain; MV: mitral valve; E:early filling; A: late filling; E': early diastolic; VP: velocity of propagation; PV: pulmonary vein; IVRT: isovolumic relaxation time; TR: tricuspid regurgitation; RV: right ventricular; TV: tricuspid valve; TAPSE: tricuspid annular plane systolic excursion; IVC: inferior vena cava. Data are expressed as mean ± SD. Functional changes of all cardiac chambers after ablation within 48 h. LA: left atrial; RA: right atrial; LAEF: left atrial ejection fraction; LASr: left atrial reservoir strain; LAScd: left atrial conduit strain; LASct: left atrial contractile strain; RAEF: right atrial ejection fraction; RASr: right atrial reservoir strain; RAScd: right atrial conduit strain; RASct: right atrial contractile strain; LV GLS: left ventricular global longitudinal strain; PSD: peak strain dispersion; LV EF: left ventricular ejection fraction; TV S’: tricuspid annular peak systolic velocity; TAPSE: tricuspid annular plane systolic excursion; RVFAC: right ventricular fractional area change; pre: pre-ablation; post: post-ablation; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns: not significant. Notably, LV diastolic function parameters E/A, E/Eʹ, isovolumic relaxation time, peak tricuspid regurgitation velocity, pulmonary vein S wave and D wave were significantly different postoperatively (p < 0.05). LV filling pressure indices (E/A, E/Eʹ) increased, relaxation parameters (isovolumic relaxation time) shorten, peak tricuspid regurgitation velocity was higher, consistent with a temporary worsening of diastolic function, even as systolic function improved. As 61.2% patients with persistent AF were in AF rhythm during pre-ablation echocardiographic assessment, the A peak was absent on echocardiography in these patients. Therefore, E/A could not be calculated in the persistent AF group. Similarly, RV diastolic function parameters, including tricuspid valve (TV) E peak velocity, TV E’ on tissue Dopple imaging, IVC diameter and IVC collapsibility index, were significantly different postoperatively compared to preoperative values. Association of AF type with echocardiographic parameters’ changes Further analysis of the magnitude of pre- and postoperative changes in relation to AF type revealed that most parameters showed no significant association with AF subtype. However, a few indicators—including RA Sr, MV A veloctiy, TV E velocity, and IVC diameter—demonstrated significant differences. Patients with persistent AF exhibited greater post-operative changes in these parameters than those with paroxysmal AF. Although the post-operative change in LA stiffness did not reach statistical significance between the two AF types, both pre- and post-operative LA stiffness values were higher in persistent AF patients compared to paroxysmal AF patients. This pattern suggests that LA remodeling is more severe in persistent AF than in paroxysmal AF (Table 5).Table 5Association of AF type in echocardiopgraphic parameters changes after ablation.Paroxysmal AFPersistent AFz value or t valuep valueLA function ΔLA ejection fraction (%)1.63 ± 12.754.51 ± 11.01− 1.280.205 ΔLA reservior strain (%)1.00 (− 3.93, 4.81)3.00 (− 1.00, 6.00)1.980.048 ΔLA conduit strain (%)− 2.36 ± 6.66− 2.00 ± 4.95− 0.320.749 ΔLA contractile strain (%)1.00 (− 2.00, 4.75)− 1.00 (− 3.00, 3.00)− 1.890.059 ΔLA stiffness0.16 (− 0.07, 0.30)0.13 (− 0.30, 0.55)− 0.2430.808 LA stiffiness pre-ablation0.57 (0.35, 0.88)1.00 (0.79, 1.63)5.05< 0.001 LA stiffiness post-ablation0.72 (0.48, 1.13)1.33 (0.84, 1.97)4.46< 0.001RA function ΔRA reservior strain (%)3.32 ± 14.318.84 ± 10.69− 2.280.024 ΔRA conduit strain (%)− 4.00 (− 11.73, 0)− 5.00 (− 9.00, − 0.50)− 0.780.436 ΔRA ejection fraction (%)7.37 ± 15.858.60 ± 16.20− 0.410.683 ΔRA min (ml)− 3.50 (− 9.00, 3.00)− 4.00 (− 13.00, 4.50)− 0.190.849LV function ΔLV global longitudinal strain (%)− 0.89 ± 3.34− 2.05 ± 3.621.790.076 ΔLV peak systolic delay (ms)− 8.05 (− 15.84, 4.45)− 6.74 (− 18.28, 2.65)− 0.460.643 ΔMV E (cm/s)− 3.00 (− 18.00, 7.23)− 5.00 (− 18.79, 5.00)− 1.680.094 ΔMV A (cm/s)− 2.50 (− 17.00, 7.75)7.0 (− 0.50, 37.5)4.29< 0.001 ΔMV E/A− 0.19 (− 0.15, 0.53)0.19 (− 0.39, 0.97)0.200.838 ΔLAT E’ (cm/s)− 2.00 (− 3.53, − 0.15)− 3.00 (− 4.00, − 1.00)− 1.380.169 ΔMED E/E'1.22 ± 2.771.27 ± 2.92− 0.100.921 ΔLAT E/E'2.39 ± 2.532.39 ± 2.51− 0.0010.999 ΔMean E/E'1.87 ± 2.371.85 ± 2.400.050.959 ΔPV S wave (cm/s)8.02 ± 21.2613.81 ± 19.12− 1.510.133 ΔPV D wave (cm/s)6.83 (− 5.63, 4.45)4.00 (− 6.00, 14.00)− 0.750.451 ΔIsovolumic relaxation time (ms)− 5.09 ± 17.78− 4.03 ± 14.37− 0.340.732 ΔPeak tricuspid regurgitation velocity (m/s)0.09 (− 0.16, 0.38)0.25 (0.03, 0.44)1.810.071 ΔRV Systolic Pressure (mmHg)3.40 ± 7.705.23 ± 6.32− 1.360.175RV function ΔTV S’ peak (cm/s)3.00 (1.00, 4.00)2.00 (0.04, 3.95)− 1.810.070 ΔTAPSE (mm)0.85 ± 4.202.13 ± 2.86− 1.960.053 ΔRV fractional area change (%)1.47 ± 9.114.28 ± 10.89− 1.520.132 ΔTV E peak (cm/s)5.78 (− 5.75, 20.00)− 2.00 (− 12.00, 13.50)− 2.360.018 TV E’ (cm/s)1.36 ± 3.86− 0.02 ± 4.511.780.078 ΔIVC max (mm)0.99 ± 4.413.28 ± 4.29− 2.820.006 ΔIVC min (mm)0.60 (− 0.69, 1.88)2.51 (0.05, 4.90)3.010.003 ΔIVC collapsibility index (%)− 3.36 (− 9.54, 3.04)− 5.57 (− 15.42, 2.83)− 1.370.171AF: atrial fibrillation; LA: left atrial; Δ: values post-ablation minus pre-ablation; RA: right atrial; LV: left ventricular; MV: mitral valve; PV: pulmonary vein; RV: right ventricular; TAPSE: tricuspid annular plane systolic excursion; TV: tricuspid valve ; IVC: inferior vena cava. Data are expressed as mean ± SD, or median (interquartile range). Table 5Association of AF type in echocardiopgraphic parameters changes after ablation.Paroxysmal AFPersistent AFz value or t valuep valueLA function ΔLA ejection fraction (%)1.63 ± 12.754.51 ± 11.01− 1.280.205 ΔLA reservior strain (%)1.00 (− 3.93, 4.81)3.00 (− 1.00, 6.00)1.980.048 ΔLA conduit strain (%)− 2.36 ± 6.66− 2.00 ± 4.95− 0.320.749 ΔLA contractile strain (%)1.00 (− 2.00, 4.75)− 1.00 (− 3.00, 3.00)− 1.890.059 ΔLA stiffness0.16 (− 0.07, 0.30)0.13 (− 0.30, 0.55)− 0.2430.808 LA stiffiness pre-ablation0.57 (0.35, 0.88)1.00 (0.79, 1.63)5.05< 0.001 LA stiffiness post-ablation0.72 (0.48, 1.13)1.33 (0.84, 1.97)4.46< 0.001RA function ΔRA reservior strain (%)3.32 ± 14.318.84 ± 10.69− 2.280.024 ΔRA conduit strain (%)− 4.00 (− 11.73, 0)− 5.00 (− 9.00, − 0.50)− 0.780.436 ΔRA ejection fraction (%)7.37 ± 15.858.60 ± 16.20− 0.410.683 ΔRA min (ml)− 3.50 (− 9.00, 3.00)− 4.00 (− 13.00, 4.50)− 0.190.849LV function ΔLV global longitudinal strain (%)− 0.89 ± 3.34− 2.05 ± 3.621.790.076 ΔLV peak systolic delay (ms)− 8.05 (− 15.84, 4.45)− 6.74 (− 18.28, 2.65)− 0.460.643 ΔMV E (cm/s)− 3.00 (− 18.00, 7.23)− 5.00 (− 18.79, 5.00)− 1.680.094 ΔMV A (cm/s)− 2.50 (− 17.00, 7.75)7.0 (− 0.50, 37.5)4.29< 0.001 ΔMV E/A− 0.19 (− 0.15, 0.53)0.19 (− 0.39, 0.97)0.200.838 ΔLAT E’ (cm/s)− 2.00 (− 3.53, − 0.15)− 3.00 (− 4.00, − 1.00)− 1.380.169 ΔMED E/E'1.22 ± 2.771.27 ± 2.92− 0.100.921 ΔLAT E/E'2.39 ± 2.532.39 ± 2.51− 0.0010.999 ΔMean E/E'1.87 ± 2.371.85 ± 2.400.050.959 ΔPV S wave (cm/s)8.02 ± 21.2613.81 ± 19.12− 1.510.133 ΔPV D wave (cm/s)6.83 (− 5.63, 4.45)4.00 (− 6.00, 14.00)− 0.750.451 ΔIsovolumic relaxation time (ms)− 5.09 ± 17.78− 4.03 ± 14.37− 0.340.732 ΔPeak tricuspid regurgitation velocity (m/s)0.09 (− 0.16, 0.38)0.25 (0.03, 0.44)1.810.071 ΔRV Systolic Pressure (mmHg)3.40 ± 7.705.23 ± 6.32− 1.360.175RV function ΔTV S’ peak (cm/s)3.00 (1.00, 4.00)2.00 (0.04, 3.95)− 1.810.070 ΔTAPSE (mm)0.85 ± 4.202.13 ± 2.86− 1.960.053 ΔRV fractional area change (%)1.47 ± 9.114.28 ± 10.89− 1.520.132 ΔTV E peak (cm/s)5.78 (− 5.75, 20.00)− 2.00 (− 12.00, 13.50)− 2.360.018 TV E’ (cm/s)1.36 ± 3.86− 0.02 ± 4.511.780.078 ΔIVC max (mm)0.99 ± 4.413.28 ± 4.29− 2.820.006 ΔIVC min (mm)0.60 (− 0.69, 1.88)2.51 (0.05, 4.90)3.010.003 ΔIVC collapsibility index (%)− 3.36 (− 9.54, 3.04)− 5.57 (− 15.42, 2.83)− 1.370.171AF: atrial fibrillation; LA: left atrial; Δ: values post-ablation minus pre-ablation; RA: right atrial; LV: left ventricular; MV: mitral valve; PV: pulmonary vein; RV: right ventricular; TAPSE: tricuspid annular plane systolic excursion; TV: tricuspid valve ; IVC: inferior vena cava. Data are expressed as mean ± SD, or median (interquartile range). Association of AF type in echocardiopgraphic parameters changes after ablation. AF: atrial fibrillation; LA: left atrial; Δ: values post-ablation minus pre-ablation; RA: right atrial; LV: left ventricular; MV: mitral valve; PV: pulmonary vein; RV: right ventricular; TAPSE: tricuspid annular plane systolic excursion; TV: tricuspid valve ; IVC: inferior vena cava. Data are expressed as mean ± SD, or median (interquartile range). Discussion Our study provides novel insights into early hemodynamic changes in AF patients following CA. The key innovation lies in our comprehensive assessment of very early functional and hemodynamic alterations across all cardiac chambers using multimodal echocardiography and bi-atrial pessures. Furthermore, this study suggested transient left ventricular diastolic dysfunction using multiple hemodynamic parameters. These findings expand understanding of acute cardiac recovery patterns post-CA and raise considerations for early post-procedural management, providing insights into how ablation impacts cardiac functions within the critical 48-h window. Biatrial pressures elevated immediately after CA All LAPs (maximum LAP, minimum LAP, and mean LAP) were significantly elevated post-ablation. Elevated LAP is one of the most critical diagnostic features of heart failure with preserved EF. As AF burden increases, particularly in patients with heart failure with preserved EF, there is a progressive decline in LA compliance and hemodynamic efficiency25,26. We speculated several factors may contribute to LAP elevation: (1) LV diastolic dysfunction (2) ablation-induced acute inflammation and edema of the atrial wall27; (3) LA stunning during the early post-procedural period, evidenced by reduced LASct28,29; (4) procedural fluid infusion. During the ablation procedure, the irrigation fluid may lead to increased blood volume, further elevating atrial pressure. This factor could represent one of the limitations in the current study. A fluid volume load of 500–800 mL was administered to each patient during the ablation. However, not all patients’ LA pressure elevated after ablation. In some patients, LA pressure decreased post-ablation. This indicated that volume increase was not the sole factor contributing to atrial pressure elevation. Prior investigations demonstrated that a rapid 500 mL fluid bolus over 8 min could acutely elevate LA pressure by 8.5 mmHg and enlarge its diameter by 4.8 mm30. In this study, the volume increase was a relatively gradual process, extending over a period of approximately 1–2 h. No statistically significant differences were observed in LA size and volume. Additionally, the left-to-right shunt caused by transseptal puncture during the ablation procedure can partially offset the LA pressure elevation induced by volume overload. Importantly, volume overload cannot lead to higher E/E’31. In this research, even after the volumetric effects resolved by the following day, echocardiographic parameters (including E/E’, peak tricuspid regurgitation velocity and E’ velocity) changed significantly, while LA and RA volume remained unchanged, which suggested persistent LV diastolic dysfunction, indicating that post-ablation LV stunning remains present. Therefore, we concluded that the elevation in LA pressure resulted from the combined effects of LV diastolic dysfunction, impaired LA compliance and volume overload. These changes collectively suggest that the acute elevation in LAP reflects both direct atrial tissue injury and secondary hemodynamic alterations. Similarly, RAPs increased significantly after CA. Elevated LAP may exacerbate tricuspid regurgitation severity and increase RV systolic pressure, resulting in secondary RAP elevation during the early post-procedural period. Comparative analysis revealed no statistically significant differences in pre- to post-procedural pressure changes between persistent AF and paroxysmal AF patients. This finding indicates that the degree of post-ablation atrial pressure elevation is comparable across AF subtypes, suggesting that the observed pressure increase is primarily attributable to the CA procedure itself and the consequent tissue injury response, rather than to the specific AF classification. CA and LA function Speckle-tracking echocardiography was employed for dynamic assessment of atrial myocardial motion. This technique has emerged as a novel approach for evaluating atrial function due to its angle independence, real-time capabilities, and quantitative measurement of global atrial performance32,33. Speckle-tracking based analysis demonstrated a significant post-procedural increase in LA Sr, LA Scd, and LA EF, whereas LA Sct was significantly decreased. The results suggested that the LA’s capacity to store pulmonary venous return during ventricular systole and passive LA emptying during early ventricular diastole was improved significantly. This interpretation aligns with the elevated S- and D-peak velocities of pulmonary venous flow observed in our results34. However, active LA contraction during late ventricular diastole was decreased post-procedure. The decrease in LA Sct may be caused by LA stunning after ablation as reported in previous studies reported35,36. Our results suggest that such mechanical stunning (especially of the LA) occurs even when sinus rhythm is restored via catheter ablation, consistent with prior observations in post-ablation atrial flutter. Besides, we show that despite this transient setback in atrial contractility, the reservoir and conduit function of the atria and the systolic function of the ventricles improve almost immediately. LA function improved more in persistent AF patients than paroxysmal AF patients. The conversion from AF to sinus rhythm rather than the ablation lesion effects could account for much of the immediate functional improvement. Therefore, the improvement of LA function may be due to restoration of sinus rhythm. Given that LA stiffness is closely associated with fibrosis27, the early phase following CA is characterized by inflammation and edema of the atrial wall, with fibrosis developing only during the later stages as inflammation gradually subsides. Our findings indicate that LA stiffness showed no significant change in the early post-ablation period, which supports this pathophysiological progression. Importantly, patients with persistent AF exhibited significantly higher LA stiffness both preoperatively and postoperatively compared to those with paroxysmal AF (p < 0.001). The correlation between elevated LA stiffness and atrial fibrosis, which serves as a key marker of LA remodeling, suggests that LA structural remodeling is more severe in patients with persistent AF compared to those with paroxysmal AF. This finding is consistent with other research37–39. CA and RA function RA systolic function improved significantly within 48 h after CA. RA systolic parameters, including RA Sr, RA Scd and RA EF, were significantly enhanced post-procedure. However, RA Sct showed no significant change. TV A-wave velocity also showed no significant difference after ablation. The absence of significant changes in both RA Sct and TV A velocity may indicate the absence of RA stunning following ablation. In addition, no significant alterations were observed in LA volumes (maximum LAV, LAV index), LA diameter (parasternal long-axis), RA maximum volume, RA volume index or RA area. These results collectively suggested that biatrial systolic function improved early after ablation, preceding structural remodeling. Compared to patients with paroxysmal AF, those with persistent AF exhibited significantly greater postoperative improvements in LA Sr and RA Sr, accompanied by more substantial reductions in IVC diameter and its respiratory variation index. These findings suggest that persistent AF is associated with more dynamic atrial strain recovery following ablation. However, no statistically significant differences were observed in other atrial functional parameters between the two groups. CA and bi-ventricular function Biventricular systolic function recovered early after CA in AF patients in the present research. The concurrent improvement in LV GLS and reduction in peak strain dispersion suggests early restoration of LV mechanical function and resynchronization during the early post-ablation period. These findings align with long-term follow-up data from prior studies33,40. Moreover, the absence of significant change in LV EF underscores the superior sensitivity of speckle-tracking echocardiography over conventional LV EF in detecting subtle, early functional improvements41,42. The observed dissociation between functional recovery (↑LVGLS, ↓peak strain dispersion) and static volumetric parameters (LVIDd, EDV) indicates that electromechanical improvements precede geometric remodeling in the early post-ablation period. Data on RV function changes post-ablation are limited. Kim et al. investigated RV function improved at 1-year follow-up after ablation43. However, the exact timing of RV functional recovery has not been reported previously. Our research explored RV function changes within 2 days after ablation. RV systolic parameters, including RVFAC, TAPSE and TV S’ velocity, increased significantly post-procedure. Minamisaka et al. reported transient LV diastolic dysfuntion, as evaluated by increased E/E’ after ablation. This research assessed LV diastolic function with multiple hemodynamic parameters, including atrial pressures, MV E peak velocity, MV E/A, E/E’, and tricuspid regurgitation velocity. In addition, we found that IVC diameter and its IVC collapsibility index also changed significantly postoperatively. When combined with elevated LAP, these observed changes following ablation collectively suggest that post-ablation diastolic stunning occurs in the LV. Based on these findings, this study suggests that during the acute phase post-ablation, fluid management is crucial. Fluid intake should be restricted, and patient weight monitoring along with assessment of signs such as lower extremity edema is recommended to prevent acute heart failure. This approach facilitates the timely identification of high-risk patients by clinicians. Limitations First, our study focused exclusively on very early post-ablation echocardiographic changes. The long-term trajectory of systolic functional recovery across all cardiac chambers following CA remains an important area for future investigation. A longitudinal study design with serial follow-up assessments would be particularly valuable for understanding the complete temporal pattern of electromechanical remodeling after ablation. Second, this was a single-center study with a modest sample size. The relatively small sample size and single-center design may limit the generalizability and statistical power of our findings. Future multicenter randomized controlled trials with larger sample sizes are warranted to confirm and extend our observations. Third, the irrigated fluid-induced volume overload may have served as a confounding factor for elevated atrial pressure in this study. Monitoring volume parameters, such as central venous pressure during the procedure, would allow for a more accurate assessment of the impact of volume status on atrial pressure changes. Conclusion This prospective study provides a comprehensive hemodynamic characterization of very early cardiac changes following CA for AF, incorporating biatrial pressure measurements and multimodality imaging assessment. Our findings suggest that systolic functional recovery of all cardiac chambers begins within 48 h post-ablation, with mechanical improvements preceding structural remodeling in AF patients. Furthermore, this study suggests transient left ventricular diastolic dysfunction by multiple hemodynamic parameters. Further mechanistic studies are warranted to elucidate the pathophysiologic processes underlying these dynamic alterations and their clinical implications for post-ablation management. Supplementary Information Supplementary Information 1. Supplementary Information 2. Supplementary Information 3. Supplementary Information 4. Supplementary Information 1. Supplementary Information 2. Supplementary Information 3. Supplementary Information 4.